Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 ...
Cantabio Pharmaceuticals reported revenue of $0 for fiscal year 2018, and net income of -$2.01 million. In Q3 2019 (the quarter ended December 31, 2018) revenue was $0. Its market capitalization was $563,600 as of February 4, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2018; market data as of February 4, 2026.
No profile data available.